Abbott Wins Off-Label Stent Marketing Suit
This article was originally published in The Gray Sheet
Executive Summary
A former Guidant salesman alleged the company marketed biliary stents off-label for use in vascular procedures. However, the company said Medicare knew biliary stents were the standard of care for arterial uses. A Texas jury sided with Abbott.
You may also be interested in...
Abbott Settlement With DOJ Highlights Feds’ Anti-Fraud Efforts
Abbott will pay $5.47 million to resolve allegations that it paid physicians for teaching assignments, speaking engagements and conferences with the expectation that they would in return facilitate product purchases at their hospitals.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.